DILANTIN-30 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dilantin-30, and what generic alternatives are available?
Dilantin-30 is a drug marketed by Viatris and is included in one NDA.
The generic ingredient in DILANTIN-30 is phenytoin. There are twenty-one drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the phenytoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dilantin-30
A generic version of DILANTIN-30 was approved as phenytoin by TARO on March 8th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DILANTIN-30?
- What are the global sales for DILANTIN-30?
- What is Average Wholesale Price for DILANTIN-30?
Summary for DILANTIN-30
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 155 |
| Clinical Trials: | 23 |
| DailyMed Link: | DILANTIN-30 at DailyMed |
Recent Clinical Trials for DILANTIN-30
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bristol-Myers Squibb | Phase 1 |
| Lawson Health Research Institute | Phase 4 |
| UCB Pharma GmbH | Phase 4 |
Pharmacology for DILANTIN-30
US Patents and Regulatory Information for DILANTIN-30
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viatris | DILANTIN-30 | phenytoin | SUSPENSION;ORAL | 008762-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
